Chemistry: molecular biology and microbiology – Process of mutation – cell fusion – or genetic modification – Introduction of a polynucleotide molecule into or...
Reexamination Certificate
2005-10-25
2005-10-25
Ketter, James (Department: 1636)
Chemistry: molecular biology and microbiology
Process of mutation, cell fusion, or genetic modification
Introduction of a polynucleotide molecule into or...
C435S375000, C424S450000
Reexamination Certificate
active
06958241
ABSTRACT:
A method of liposome-based therapy for a mammalian subject is disclosed. The method uses liposomes with outer surfaces that contain an affinity moiety effective to bind specifically to a biological surface at which the therapy is aimed, and a hydrophilic polymer coating effective to shield the affinity moiety from interaction with the target surface. The hydrophilic polymer coating is made up of polymer chains covalently linked to surface lipid components in the liposomes through releasable linkages. After a desired liposome biodistribution is achieved, a releasing agent is administered to cause cleaving of a substantial portion of the releasable linkages in the liposomes, to expose the affinity agent to the target surface.
REFERENCES:
patent: 4935465 (1990-06-01), Garman
patent: 5013556 (1991-05-01), Woodle et al.
patent: 6043094 (2000-03-01), Martin et al.
patent: 6660525 (2003-12-01), Martin et al.
patent: 0 317 957 (1989-05-01), None
patent: 0 526 700 (1993-02-01), None
patent: WO 94/21281 (1994-09-01), None
Copy of International Search Report for PCT/US97/18813.
Allen et al., “A new strategy for attachment of antibodies to sterically stabilized liposomes resulting in efficient targeting to cancer cells”, Biochimica et Biophysica Acta 1237 (1995); pp. 99-108.
Anwer et al., “Optimization of Cationic Lipid/DNA Complexes for Systemic Gene Transfer to Tumor Lesions”, Journal of Drug Targeting vol. 8, No. 2 (2000); pp. 125-135.
Baldwin et al., “Effect on Polymyxin B on Experimental Shock from Meningococcal and Escherichia coli Endotoxins”, The Journal of Infectious Diseases 164 (1991); pp. 542-549.
Blume et al., “Specific targeting with poly(ethylene glycol)-modified liposomes: coupling of homing devices to the ends of the polymeric chains combines effective target binding with long circulation times”, Biochimica et Biophysica Acta 1149 (1993); pp. 180-184.
Bone, “The Pathogenesis of Sepsis”, Annals of Internal Medicine 115 (1991); pp. 457-469.
Capon and Ward, “The CD4-gp120 Interaction and Aids Pathogenesis”, Annual Review of Immunology 9 (1991); pp. 649-678.
Defrees et al., “Sialyl Lewis x Liposomes as a Multivalent Ligand and Inhibitor of E-Selectin Mediated Cellular Adhesion”, Journal of the American Chemical Society 118 (1996); pp. 6101-6104.
Dinarello, “Interleukin-1 and Interleukin-1 Antagonism”, Blood vol. 77, No. 8 (1991); pp. 1627-1652.
Friedmann, “Overcoming the Obstacles to Gene Therapy”, Scientific American (1997); pp. 96-101.
Haynes, “Scientific and Social Issues of Human Immunodeficiency Virus Vaccine Development”, Science 260 (1993); pp. 1279-1286.
Heath et al., “Covalent Attachment of Immunoglobulins to Liposomes Via Glycosphingolipids”, Biochimica et Biophysica Acta 640 (1981); pp. 66-81.
Humphries et al., “A Synthetic Peptide from Fibronectin Inhibits Experimental Metastasis of Murine Melanoma Cells”, Science 233 (1986); pp. 467-470.
Ichikawa et al., “Chemical-Enzymatic Synthesis and Conformational Analysis of Sialyt Lewis x and Derivatives”, Journal of the American Chemical Society 114 (1992); pp. 9283-9298.
Kano et al., “The Activation of cAMP-Dependent Protein Kinase is Directly Linked to the Inhibition of Osteoblast Proliferation (UMR-106) by Parathyroid Hormone-Related Protein”, Biochemical and Biophysical Research Communications vol. 174, No. 3 (1991); pp. 97-101.
Kawasaki et al., “Amino Acids and Peptides.XIV. Laminin Related Peptides and Their Inhibitory Effect on Experimental Metastasis Formation”, Biochemical and Biophysical Research Communications vol. 174, No. 3 (1991); pp. 1159-1162.
Kirpotin et al., “Liposomes with detachable polmer coating: destabilization and fusion of dioleoylphosphatidylethanolamine vesicles triggered by cleavage of surface-grafted poly(ethylene glycol)”, FEBS Letters 388 (1996); pp. 115-118.
Klibanov and Huang, “Long-Circulating Liposomes: Development and Perspectives”, Journal of Liposome Research vol. 2, No. 3 (1992); pp. 321-334.
Martin et al., “Immunospecific Targeting of Liposomes to Cells: A Novel and Efficient Method for Covalent Attachment of Fab' Fragments via Disulfide Bonds”, Biochemistry 20 (1981); pp. 4229-4238.
Martin and Papahadjopoulos, “Irreversible Coupling of Immunoglobulin Fragments to Preformed Vesicles”, Journal of Biological Chemistry vol. 257, No. 1 (1982); pp. 286-288.
Martin, “Pharmaceutical Manufacturing of Liposomes”, Chapter 6, Specialized Drug Delivery Systems: Manufacturing and Production Technology (Marcel Dekker, Inc, New York and Basel) (1990); pp. 267-316.
Phillips et al., “ELAM-1 Mediates Cell Adhesion by Recognition of a Carbohydrate Ligand, Sialyi-Le”, Science 250 (1990); pp. 1130-1132.
Robbins and Ghivizzani, “Viral Vectors for Gene Therapy”, Pharmacology & Therapeutics vol. 80, No. 1 (1998); pp. 35-47.
Schofield and Caskey, “Non-viral approaches to gene therapy”, British Medical Bulletin vol. 51, No. 1 (1995); pp. 56-71.
Stylianou et al., “Interleukin 1 Induces NF-KB through Its Type I but Not Its Type II Receptor in Lymphocytes”, Journal of Biological Chemistry vol. 267, No. 22 (1992); pp. 15836-15841.
Szoka, “Comparative Properties and Methods of Preparation of Lipid Vesicles (Liposomes)”, Annual Review of Biophysics and Bioengineering 9 (1980); pp. 467-508.
Uster et al., “Insertion of poly(ethylene glycol) derivatized phospholipid into pre-formed liposomes results in prolonged in vivo circulation time”, FEBS Letters 386 (1996); pp. 243-246.
Waldmann, “Immune Receptors: Targets for Therapy of Leukemia/Lymphoma, Autoimmune Diseases and for the Prevention of Allograft Rejection”, Annual Review of Immunology 10 (1992); pp. 675-704.
Yuan et al., “Vascular Permeability in a Human Tumor Xenograft: Molecular Size Dependence and Cutoff Size”, Cancer Research 55 (1995); pp. 3752-3756.
Zalipsky and Lee, “Use of Functionalized Poly(Ethylene Glycol)s for Modification of Polypeptides”, Chapter 21, Poly(Ethylene Glycol) Chemistry: Biotechnical and Biomedical Applications (J. Milton Harris. Plenum Press, New York) (1992); pp. 347-370.
Zalipsky et al., “Evaluation of a New Reagent for Covalent Attachment of Polyethylene Glycol to Proteins”, Biotechnology and Applied Biochemistry 15 (1992); pp. 100-114.
Zalipsky, “Synthesis of an End-Group Functionalized Polyethylene Glycol-Lipid Conjugate for Preparation of Polymer-Grafted Liposomes”, Bioconjugate Chemistry 4 (1993); pp. 296-299.
Zalipsky et al., “Long circulating, cationic liposomes containing amino-PEG-phosphatidylethanolamine”, FEBS Letters 353 (1994); pp. 71-74.
Zalipsky, “Polyethylene Glycol-Lipid Conjugates”, Chapter 9, Stealth Liposomes (CRC Press) (1995); pp. 93-102.
Huang Shi Kun
Martin Francis J.
Zalipsky Samuel
Atkins Michael
Katcheves Konstantina
Ketter James
LandOfFree
Therapeutic liposome composition and method does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic liposome composition and method, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic liposome composition and method will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3486964